Amy Duross Sells 1,000 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) Director Amy Duross sold 1,000 shares of the business’s stock in a transaction on Friday, November 21st. The shares were sold at an average price of $26.00, for a total transaction of $26,000.00. Following the sale, the director directly owned 24,687 shares of the company’s stock, valued at approximately $641,862. The trade was a 3.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Amy Duross also recently made the following trade(s):

• On Thursday, November 20th, Amy Duross sold 4,523 shares of BioLife Solutions stock. The shares were sold at an average price of $24.51, for a total value of $110,858.73.
• On Wednesday, November 19th, Amy Duross sold 477 shares of BioLife Solutions stock. The stock was sold at an average price of $24.50, for a total value of $11,686.50.

BioLife Solutions Stock Performance

Shares of NASDAQ BLFS traded up $2.33 during trading on Friday, hitting $26.53. The company had a trading volume of 540,117 shares, compared to its average volume of 456,202. BioLife Solutions, Inc. has a 12 month low of $19.10 and a 12 month high of $29.62. The firm has a market capitalization of $1.28 billion, a P/E ratio of -221.06 and a beta of 1.97. The stock has a 50 day simple moving average of $26.36 and a 200 day simple moving average of $24.10.

Analysts Set New Price Targets

Several research firms recently weighed in on BLFS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective (up previously from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. Finally, Zacks Research raised shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.20.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Hantz Financial Services Inc. increased its holdings in BioLife Solutions by 54.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock worth $48,000 after buying an additional 659 shares during the period. State of Wyoming increased its stake in shares of BioLife Solutions by 353.1% in the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 1,490 shares during the period. Quarry LP raised its holdings in shares of BioLife Solutions by 50.9% during the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 713 shares during the last quarter. US Bancorp DE lifted its position in BioLife Solutions by 243.7% during the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock valued at $49,000 after purchasing an additional 1,528 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its holdings in BioLife Solutions by 12.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after purchasing an additional 441 shares during the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.